Novel H-2D<sup>b</sup>-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice

We identified the first CD8<sup>+</sup> T-cell epitope of the MAGE-type P1A tumor antigen presented in the H-2<sup>b</sup> background. This opens new perspectives for mechanistic studies dissecting MAGE-type specific antitumor immunity, making use of the wealth of genetically altered mouse strains available in the C57BL/6 background. This should facilitate the advancement of specific cancer immunotherapies.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2024-10-01
DOI
https://doi.org/10.1136/jitc-2024-008998
Citations
1
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.24

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice

Vinnycius Pereira Almeida, Maryam Ahmad, James McAuliffe, Vineethkrishna Chandrasekar et al.
1 citations
Journal for ImmunoTherapy of Cancer
Immunotherapy and Immune Responses
0.24
article

Novel H-2Db-restricted CD8 epitope derived from mouse MAGE-type antigen P1A mediates antitumor immunity in C57BL/6 mice

Vinnycius Pereira Almeida, Maryam Ahmad, James McAuliffe, Vineethkrishna Chandrasekar, Nathalie Vigneron, Laurine Noblecourt, Emily E Steffke, Benoı̂t J. Van den Eynde, Ramiro A. Ramirez-Valdez, Amanda Wicki, Carol Sze Ki Leung, Julie Lesenfants, Vincent Stroobant, Silvia Panetti, Yushu Hu, Shi Yu William Guo
article en
1 citations

Abstract

We identified the first CD8<sup>+</sup> T-cell epitope of the MAGE-type P1A tumor antigen presented in the H-2<sup>b</sup> background. This opens new perspectives for mechanistic studies dissecting MAGE-type specific antitumor immunity, making use of the wealth of genetically altered mouse strains available in the C57BL/6 background. This should facilitate the advancement of specific cancer immunotherapies.

Journal for ImmunoTherapy of CancerVol. 12(10)
University of Verona (IT), Ludwig Cancer Research (BE), University of Oxford (GB), Ludwig Cancer Research (GB), de Duve Institute (BE), Walloon Excellence in Lifesciences and Biotechnology (BE)
National Science Foundation, Ludwig Institute for Cancer Research, Cancer Research UK, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Good health and well-being
Openalex Percentile: Top 42%
Immunotherapy and Immune Responses
0.24
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.